Literature DB >> 805659

A study of cyst fluid and plasma carcinoembryonic antigen in patients with cystic ovarian neoplasms.

J R van Nagell, Q A Pletsch, D M Goldenberg.   

Abstract

Cyst fluid and plasma carcinoembryonic antigen (CEA) levels were measured in 11 patients with ovarian cyst-adenocarcinoma and in 16 patients with benign ovarian neoplasms. In patients with ovarian cancer, plasma CEA levels were not elevated above 2.5 ng/ml unless cyst fluid CEA levels were 4 to 16 mu-g/ml. In this series, cystic and plasma CEA levels were elevated most consistently in patients with mucinous ovarian tumors. Furthermore, on the basis of molecular size and immunoreactivity by immunodiffusion, ovarian cancer cyst fluid CEA and colonic cancer CEA had similar immunochemical properties. Consistent with the findings in other neoplasms, follow-up studies showed that plasma CEA levels returned to the normal range between 2 and 12 weeks after surgical excision of the ovarian tumor. It is concluded that plasma CEA is of value in the management of patients with ovarian mucinous cystadenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 805659

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  An immunohistochemical study of distribution of carcinoembryonic antigen in epithelial tumours of the ovary.

Authors:  J Heald; C H Buckley; H Fox
Journal:  J Clin Pathol       Date:  1979-09       Impact factor: 3.411

2.  Asymptomatic primary mucinous cystadenocarcinoma of the appendix with a large abdominal mass: report of a case.

Authors:  A Suto; A Tsuyuki; N Hiraoka; Y Hosoda; K Kikuchi; Y Fujishiro
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

3.  Products of gynaecological neoplasms: clinical and pathological applications.

Authors:  A M Neville
Journal:  Arch Gynecol       Date:  1980

4.  Serum levels of six tumor markers in patients with benign and malignant gynecological disease.

Authors:  I Fukazawa; N Inaba; Y Ota; N Sato; S Shirotake; H Iwasawa; T Sato; H Takamizawa; B Wiklund
Journal:  Arch Gynecol Obstet       Date:  1988       Impact factor: 2.344

5.  Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA.

Authors:  H Halila; M L Huhtala; C Haglund; S Nordling; U H Stenman
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640

6.  Tumour-associated trypsin inhibitor (TATI) in ovarian cancer.

Authors:  H Halila; P Lehtovirta; U H Stenman
Journal:  Br J Cancer       Date:  1988-03       Impact factor: 7.640

7.  A comparison of the growth promoting properties of ascitic fluids, cyst fluids and peritoneal fluids from patients with ovarian tumours.

Authors:  A P Wilson; H Fox; I V Scott; H Lee; M Dent; P R Golding
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.